Newsroom

Industry News

23 Mar

BioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of Immuno-Oncology Pipeline

TEL AVIV, Israel, March 23, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it has acquired Agalimmune Ltd., a private UK-based company with an innovative, anti-cancer immunotherapy platform. Acquisition consideration consisted of a $6 million upfront payment, of...

Read more

23 Mar

BioLineRx Reports Year End 2016 Financial Results

TEL AVIV, Israel, March 23, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ: BLRX,  TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the year ended December 31, 2016. Highlights and achievements in 2016 and to date: Acquired Agalimmune Ltd., a UK-based biopharmaceutical company...

Read more

22 Mar

NEMUS Bioscience and the University of Mississippi Announce Significant Anti-MRSA Synergy Data Utilizing Proprietary Cannabinoid-Based Anti-Infective Platforms

COSTA MESA, CA–(Marketwired – Mar 22, 2017) – NEMUS Bioscience, Inc. ( OTCQB : NMUS ) and the company’s discovery and research partner, the University of Mississippi (UM), today announced that bactericidal synergy was achieved against multiple species of methicillin-resistant Staphylococcus aureus (MRSA) utilizing a proprietary cannabinoid-based therapeutic platform. MRSA...

Read more

21 Mar

Actinium Announces Receipt of Positive Scientific Advice from the European Medicines Agency for Iomab-B

NEW YORK, March 21, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has received positive Scientific Advice from the Committee for Medicinal Products for Human...

Read more

21 Mar

Update on Full Six-Patient Cohort Confirms Patients with Complete Paralysis Can Experience Meaningful Recovery of Function by Six Months Following AST-OPC1 Treatment

FREMONT, Calif., March 21, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, reported that including the sixth and final patient in the AIS-A 10 million cell cohort in the company’s ongoing SCiStar Phase 1/2a clinical trial has further confirmed...

Read more

21 Mar

George Bickerstaff Elected to Inovio’s Board of Directors

PLYMOUTH MEETING, Pa., March 21, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) announced today the election of George Bickerstaff to its Board of Directors. Mr. Bickerstaff is an internationally recognized expert in finance, healthcare and information technology.  He has served Novartis Pharma AG as its chief financial officer...

Read more

21 Mar

Youngevity International, Inc (YGYI) to Host Full Year 2016 Earnings Call

SAN DIEGO, CA–(Marketwired – Mar 21, 2017) – Youngevity International, Inc. ( OTCQX : YGYI ) (www.YGYI.com), a leading omni-direct lifestyle company, announced today that it will host a conference call on Thursday, March 30th at 4:15 PM Eastern Daylight Time (1:15 PM Pacific Daylight Time), to discuss the...

Read more

21 Mar

Onconova Therapeutics, Inc. to Present at Two Upcoming Healthcare Conferences

NEWTOWN, Pa., March 21, 2017 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Company management will present an overview at the Sachs Fifth Annual Cancer Bio Partnering and Investment Forum,...

Read more

Page 1 of 22212345...102030...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address